LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

11.64 -2.51

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.22

Máximo

11.84

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.522 50.102
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+66.81% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B
Apertura anterior	14.15
Cierre anterior	11.64

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

7 / 344 Clasificación en Healthcare

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 may 2026, 16:52 UTC

Noticias de Eventos Importantes

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q Rev $1.76B >SQM

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q EPS $1.28 >SQM

26 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q EPS $11.61 >WEBC

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q Sales $179.6M >WEBC

26 may 2026, 21:48 UTC

Charlas de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 may 2026, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

26 may 2026, 20:58 UTC

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 19:22 UTC

Charlas de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 may 2026, 19:17 UTC

Charlas de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 may 2026, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 may 2026, 18:03 UTC

Charlas de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 may 2026, 17:42 UTC

Charlas de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 may 2026, 17:33 UTC

Charlas de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 may 2026, 17:21 UTC

Charlas de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 may 2026, 16:52 UTC

Charlas de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 may 2026, 16:43 UTC

Charlas de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 may 2026, 16:24 UTC

Charlas de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 may 2026, 16:21 UTC

Charlas de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

26 may 2026, 16:16 UTC

Charlas de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 may 2026, 16:01 UTC

Charlas de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 may 2026, 15:21 UTC

Charlas de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

66.81% repunte

Estimación a 12 Meses

Media 20 USD 66.81%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Sentimiento

By Acuity

7 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.